ITOC 2020 | Translation into therapeutic strategies: the ADAR pathway

Jeffrey Ishizuka, MD, DPhil, Yale School of Medicine, New Haven, CT, explains the challenges facing ADAR targeting. He suggests that a small molecule approach or genetically targeting ADAR could be a way to overcome immunotherapy resistance, but highlights that continuous research is needed in order to use ADAR inhibition as a therapeutic strategy. This interview took place during the 7th Immunotherapy of Cancer Conference (ITOC) 2020.